Novel Synthesis of Iduronate a Heparan Sulphate Subunit

BACKGROUND Heparan sulphate and heparin play a central role in a large number of processes including anti-coagulation, angiogenesis, cell growth and migration. A new class of medicinal drugs can be envisaged that would either promote or inhibit the function of heparan sulfate/heparin by mimicking or competitively inhibiting the function of heparan sulphate/heparin. These types of complex heparan sulphate molecules have historically been difficult to synthesise and the majority could be obtained only by chromatographic methods particularly if the iduronate sugar subunit was part of the molecule. THE TECHNOLOGY We have developed the first synthesis of iduronate using relatively inexpensive reagents at room temperature. We have increased the yield, demonstrated that the process can be scaled up and have combined the saccharide with other saccharides, which form the basis of a new class of glycotherapeutic molecules. Such physiologically active molecules could be used to treat cancer, heart disease, rheumatoid arthritis or Alzheimer’s disease KEY BENEFITS
• Scalable synthesis to yield clinical grade material in bulk
• Straightforward synthesis conditions
• Significantly reduced costs
• Efficient and effective glycotherapeutic development POTENTIAL APPLICATIONS The therapeutic potential of these compounds includes
• Cardiology/vascular medicine (anti-coagulation),
• Cancer (angiogenesis and tumour growth),
• Diabetic retinopathy (angiogenesis)
• Rheumatoid arthritis (angiogenesis in the pannus)
• Alzheimer’s disease.PATENT STATUS Patent filed. Protection will also be sought for specific new chemical entities generated. OPPORTUNITY Collaborative development and licence opportunity, of interest to Pharma and Biotech companies

Type of Offer: Licensing

Next Patent »
« More Healthcare Patents
« More Pharmaceutical Patents

Share on      

CrowdSell Your Patent